Bücherschau

Wegner, U.; Hahn, H. G.; Witt, W.; Hahnemann, H. W.; Stange, K.; Hoffmann, G.; Zehner, P.

doi:10.1007/bf02560836

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[64] PZQ showedc ure rates of 75-85 %f or S. haematobium,6 3-85 %f or S. mansoni,8 0-90 % for S. japonicum infections, and 60-80 %f or co-infections with S. mansoni and S. haematobium. [65] PZQ has as tereocenter at the 11b-position,a nd anthelmintic activity wasf ound to be associatedw ith the R enantiomer. [66,67] The recommended dose of 9 is 40 mg kg À1 to treat S. mansoni, S. haematobium and S. intercalatum infections; [68] ah igher dose of 60 mg kg À1 is neededf or S. japonicum.…”

Section: Praziquantelmentioning

confidence: 99%

Chemotherapy for Fighting Schistosomiasis: Past, Present and Future

et al. 2018

View full text Add to dashboard Cite

Chemotherapy based on repeated doses of praziquantel remains the most effective control strategy against schistosomiasis, a neglected tropical disease caused by platyhelminths of the genus Schistosoma spp. Its long-term use, however, raises serious concerns about drug resistance against praziquantel. Therefore, it is generally acknowledged that alternative treatment options are urgently needed. This Review summarizes data on relinquished drugs as well as recent advances in the area of antischistosomal compounds from a medicinal chemistry point of view. Furthermore, insights into the structure-activity relationships of each class of compounds are presented including in vitro and in vivo data, if available. Although many compounds have demonstrated good antischistosomal activity in vitro, they offer little promise to replace praziquantel. Nevertheless, the race to develop novel antischistosomal agents is ongoing.

show abstract